The PRV was granted to Zevra in September 2024 following approval by the U.S. Food and Drug Administration of MIPLYFFA, which is indicated for use in combination with miglustat for the treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback